
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Following treatment with IV- or IM-administered alefacept (Amevive), more than 1,000 patients with chronic plaque psoriasis showed insignificant levels of drug-related antibody.